


# Malaria: when the need for chemoprophylaxis is not clear-cut

Dr Ula Maniewski

11th National Seminar on Travel Medicine

Thursday 19th November 2015





# ABCDE of malaria prevention for travellers

- **A: Awareness**
- **B: Bite prevention**
- **C: Chemoprophylaxis**, if indicated.
- **D: Diagnosis**
- **E: Environment**: Avoid outdoor activities in environments that are mosquito breeding places, especially in late evenings and at night.



# Malaria prevention

- Chemoprophylaxis
  - Atovaquone/proguanil (-1d;+7d)
  - Mefloquine 1/w (-2w;+4w)
  - Doxycycline 100 mg 1/d (-1d;+28d)
  - Chloroquine 300 mg 1x/w (-1w;+4w)



# Who Needs Drug Prophylaxis against Malaria?

## My Personal View

*Lars Rombo*

A long tradition of successful malaria prophylaxis with chloroquine led to a dogma that drug prophylaxis should be given regardless of risk as soon as a traveler entered endemic areas. This prevailed also when resistance to chloroquine and adverse effects of alternatives became a problem. A cost/benefit analysis of the risk for malaria versus risk for adverse effects and cost of the recommended drug is not uniformly applied and drug prophylaxis is still advocated even when the risk for severe adverse effects greatly exceeds the risk for malaria, which is unethical.

J Travel med, 2005

In low malaria risk areas, whether or not prescribing chemoprophylaxis is not always a clear-cut decision



# The choice of prevention depends on:

## 1) Risk to get malaria

- Depends on the region, but can vary locally
- Depends on activities (how to spend evenings/ nights)
- Can vary in different seasons
- Can vary between locals-travellers-expats

## 2) Which type of malaria one expects (P falciparum, P non falciparum, resistance)

In low malaria risk areas, the advice is nuanced, **taking into account the preferences of the traveller**



RESEARCH

Open Access

# Recommendations for malaria prevention in moderate to low risk areas: travellers' choice and risk perception

Switzerland

Rachel Voumard<sup>1</sup>, Delphine Berthod<sup>2</sup>, Clotilde Rambaud-Althaus<sup>3</sup>, Valérie D'Acremont<sup>1,3</sup> and Blaise Genton<sup>1,2,3\*</sup>

## Abstract

When travelling to moderate- to low-risk malaria areas, **85%** of interviewees **chose not to take** chemoprophylaxis as malaria prevention, although most (*non-Swiss*) guidelines recommend it.

*... hence **15%** of interviewees **chose to take** chemoprophylaxis as malaria prevention, although Swiss guidelines **do not** recommend it...*

They had coherent reasons for their choice.

New recommendations should include **shared decision-making** to take into account **travellers' preferences**.

	Malaria risk	Type of prevention
Type A	Very limited risk of malaria	Mosquito bite prevention only transmission
Type B A/B	<del>Risk of <i>P. vivax</i> malaria only</del> or (very) low risk of <i>P. falciparum</i>	<del>Mosquito bite prevention plus chloroquine or doxycycline or mefloquine chemoprophylaxis (select according to reported side-effects and contraindications)<sup>a</sup></del> Mosquito bite prevention + think of malaria when T° + /- chemoprophylaxis intermittent or SBET
Type C	Risk of <i>P. falciparum</i> with reported chloroquine and sulfadoxine-pyrimethamine resistance	Mosquito bite prevention plus malaria, atovaquone-proguanil or doxycycline or mefloquine chemoprophylaxis (select according to reported side-effects and contraindications) <sup>a</sup>
Type D	<del>Risk of <i>P. falciparum</i> malaria in combination with reported multidrug resistance</del>	<del>Mosquito bite prevention plus atovaquone-proguanil or doxycycline or mefloquine chemoprophylaxis (select according to reported drug resistance pattern, side-effects and contraindications)<sup>a,b</sup></del>

<sup>a</sup>Alternatively, for travel to rural areas with low risk of malaria infection, mosquito bite prevention can be combined with stand-by emergency treatment (SBET).



# Belgian Consensus 2015

*“In most regions in **Asia & Latin America** (see map of the German-speaking countries: <http://www.dtg.org/21.0.html>), **one can decide not to take continuously malaria tablets** (chemoprophylaxis) **after a thorough evaluation of the risk**. The malaria risk is mostly low to negligible, even for adventurous travellers and/or long term travelers, and depends on the specific region, the season, rural vs urban stay, but foremost on the quality of accommodation for the night, and on the availability of a good quality local health care providing reliable malaria diagnosis and appropriate treatment. It is imperative to **avoid always mosquito bites** between sunset and sunrise, by means of repellents and mosquito nets. A fever that appears during or after travel to a region with a low malaria risk may still be due to malaria. This diagnosis has to be ruled out, even if the absolute risk is very low. In case different regions are visited (with a generally low regional malaria-risk, but probably locally more elevated malaria risk) there are some more options besides continuous malaria chemoprophylaxis. A **“standby emergency treatment (SBET)”** (e.g. atovaquone/proguanil) can be carried in the travel kit with complete instructions how and when to use. and/or a planning for the **temporarily malaria chemoprophylaxis** (atovaquone/proguanil) based on the regional malaria risk, when the malaria risk in the region visited is sufficiently high\_ (information on [www.itg.be](http://www.itg.be)).”*





# Which strategies exist in low malaria risk areas?

## GERMAN SPEAKING EUROPE

- Bite prevention always
- **AND** think of malaria when sick

- Standby emergency treatment


## BELGIUM

- Bite prevention always
- **AND** think of malaria when sick

- Chemoprophylaxis when risk is locally/ circumstances higher
- SBET in some cases






### Countries with ongoing transmission of malaria, 2013




# Malariaprophylaxe 2015

Einteilung in Zonen mit unterschiedlicher medikamentöser Chemoprophylaxe gemäß den Empfehlungen der DTG - Deutschen Gesellschaft für Tropenmedizin und Internationale Gesundheit  
Stand: April 2015

Für alle Malariagebiete gilt:  
Mückenschutz empfohlen  
(minimales Risiko siehe Länderliste)

-  Gebiete, wo die Malaria nicht oder nicht mehr vorkommt
-  Gebiete mit sehr beschränktem Malariarisiko: Malariaübertragung selten
-  Gebiete mit Malariaübertragung


- P** Zur Chemoprophylaxe Atovaquon/Proguanil (Malarone®) oder Doxycyclin\* oder Mefloquin (Lariam®)\*\*  
\* Für diese Indikation in Deutschland nicht zugelassen  
\*\* Besondere Warnhinweise beachten
- T** Zur Notfalltherapie Atovaquon/Proguanil (Malarone®) oder Artemether/Lumefantrin (Riamet®)  
Keine Chemoprophylaxe empfohlen
- CT** Chloroquin zur Notfalltherapie  
Keine Chemoprophylaxe empfohlen
- P\*** Chemoprophylaxe saisonal empfohlen mit Atovaquon/Proguanil (Malarone®) oder Doxycyclin\* oder Mefloquin (Lariam®)\*\*  
\* Für diese Indikation in Deutschland nicht zugelassen  
\*\* Besondere Warnhinweise beachten  
Ansonsten Notfalltherapie Atovaquon/Proguanil (Malarone®) oder Artemether/Lumefantrin (Riamet®)



Grafik: Pechel / InterMEDIS

Angepasst an WHO, World Malaria Report 2014, WHO International Travel And Health 2014, Swiss TPH, Basel/ B.R. Beck; Universität Zürich/ISPMZ; M. Funk



# Malaria 2015 (source WHO 2010, World Malaria Report 2014)



for details : see [www.itg.be](http://www.itg.be)



# Declining incidence of imported malaria in the Netherlands, 2000-2007




Americas: risk 1/100,000

Asia: risk 1-4/100,000




Van Rijckevorsel et al. *Malar J* 2010

# Declining incidence of imported malaria in the Netherlands, 2000-2007



Africa: risk 10-400/100,000

# Some examples in Asia



WHO 2014: Confirmed malaria cases/1000 pers in 2013





# India

Tropimed US: risk in all areas < 2000m



Tropimed© US 2015

Tropimed© Swiss 2015

# UK guidelines


FIGURE 3 INDIA SHOWING THE STATES WITH APPROPRIATE CHEMOPROPHYLAXIS RECOMMENDED



FIGURE 3 INDIA SHOWING THE STATES WITH APPROPRIATE MALARIA PREVENTION MEASURES RECOMMENDED




# Malaria 2015



“ Het risico voor **resistente falciparum malaria** kan hoog zijn in de staat Assam, Orissa een klein gedeelte van de staat Andhra Pradesh, een klein gedeelte van de staat Madhya Hier is de inname van malariatabletten aangewezen zoals in zone C.”



# Sri Lanka



<http://journals.plos.org/plosone/article?id=info:doi/10.1371/journal.pone.0043162>

PLOS ONE



WHO 2015: no malaria cases locally acquired since oct 2012. Before 88% P vivax





# Viet Nam



Tropimed © US, 2015





Tropimed ©Swiss, 2015



ITG, 2015



# Indonesia



**Figure 2** Annual Parasite Index (API) per province and compared with country total API, 2013 (data from Indonesian MoH).

*J Travel Med 2015; 22: 389–395*

# Indonesia WHO report 2010



Insufficient data 0 0-0.1 0.1-1.0 1.0-10 10-50 50-100 ≥100

Distribution of confirmed malaria cases (per 1 000 population)








# Indonesia

## Malaria Endemic Areas

- Risk areas**  
all areas of eastern Indonesia (prov. of Maluku, Maluku Utara, Nusa Tenggara Timur, Papua, and Papua Barat) incl. town of Labuan Bajo and Komodo Islands in the Nusa Tenggara region; rural areas of Kalimantan (Borneo), Nusa Tenggara Barat (incl. the island of Lombok), Sulawesi, and Sumatra
- Low transmission in rural areas of Java** incl. Pangandaran, Sukalumi, and Ujung Kulong
- Malaria-free**  
Jakarta, Ubud, resort areas of Bali and Java, and Gili Islands, and the Thousand Islands (Pulau Seribu)





# Philippines



Tropimed © Swiss, 11-2015



Tropimed © US 11-2015



WHO 2014




Travax 2015






# Some examples in South America



PAHO 2015



## Malaria Journal



Opinion

Open Access

### The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis?

Ron H Behrens<sup>\*1,2</sup>, Bernadette Carroll<sup>1</sup>, Jiri Beran<sup>3</sup>, Olivier Bouchaud<sup>4</sup>, Urban Hellgren<sup>5</sup>, Christoph Hatz<sup>6</sup>, Tomas Jelinek<sup>7</sup>, Fabrice Legros<sup>8</sup>, Nikolai Mühlberger<sup>9</sup>, Bjørn Myrvang<sup>10</sup>, Heli Siikamäki<sup>11</sup>, Leo Visser<sup>12</sup> for TropNetEurop



# Bolivia

Tropimed© US-2015



## Bolivia

Malaria Endemic Areas

- Risk in all areas <2,500 m (<8,202 ft)
- Malaria-free including city of La Paz
- National Park NP
- Integrated Management Natural Area IMNA
- Wildlife National Reserve WNR

Tropimed © Swiss-2015



## Bolivie

Zones d'endémie du paludisme




- Risque faible < 2500 m  
Paludisme dû aux *P. falciparum* à Santa Cruz et dans les départements du nord Beni et Pando, surtout dans les villes de Guayaramerin, Itinez et Riberalta
- Pas de paludisme  
villes, provinces Oruro et Potosi
- Parc National PN
- Aire Naturelle de Gestion Intégrée ANGI
- Réserve Nationale de la Vie Sauvage RNVS

Aires protégés

- |                       |                      |
|-----------------------|----------------------|
| 1 Sajama PN/ANGI      | 13 Pilon Lajas ANGI  |
| 2 Tunari PN           | 14 El Palmar ANGI    |
| 3 Isiboro Sécure PN   | 15 San Matias ANGI   |
| 4 Noel Kempff PN      | 16a Amboró PN        |
| 5 Torotoro PN/ANGI    | 16b Amboró ANGI      |
| 6 Carrasco PN         | 17 Cotapata PN/ANGI  |
| 7 Eduardo Avaroa RNVS | 18 Madidi PN         |
| 8 Manuripi RNVS       | 19a Kaa Iya PN       |
| 9 Tariquia RNVS       | 19b Kaa Iya ANGI     |
| 10 Sama RNVS          | 20a Otuquis PN       |
| 11 Apolobamba ANGI    | 20b Otuquis ANGI     |
| 12 EBB ANGI           | 21 Aguaraque PN/ANGI |



# Bolivia



# Brazil








FIGURE 6 MAP OF BRAZIL SHOWING THE STATES WHERE CHEMOPROPHYLAXIS IS REQUIRED



Select (Prevention & Treatment)



# Panama



Low to no risk  
antimalarials not  
usually advised

Surrounding  
countries with  
malaria risk


Fitfortravel, 2015



PAHO, 2015

# Suriname

PAHO, 2015



WHO, 2015



Tropimed© Swiss+ US 2015

Institute of Tropical Medicine




LCI, Van Ginderen, CISTM 14




# French Guyane



WHO, 2014



ARS, Guyane, 2015



PAHO, 2015






# Peru



Tropimed©US 2015

Tropimed©Swiss 2015



Travax 2015

ITG 2015







Bedankt voor uw aandacht

